A detailed history of Marshall Wace, LLP transactions in Rallybio Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 29,032 shares of RLYB stock, worth $38,902. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,032
Previous 15,025 93.22%
Holding current value
$38,902
Previous $35,000 51.43%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.25 - $2.4 $17,508 - $33,616
14,007 Added 93.22%
29,032 $53,000
Q4 2023

Feb 14, 2024

BUY
$1.91 - $4.39 $28,697 - $65,959
15,025 New
15,025 $35,000

Others Institutions Holding RLYB

About Rallybio Corp


  • Ticker RLYB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,132,000
  • Market Cap $43.1M
  • Description
  • Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...
More about RLYB
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.